The Innovative Regional Growth Core PRAEMED.Bio is a project funded by the BMBF with a duration of 3 years 01.01.2019 - 31.12.2021. Companies and research institutions like attomol GmbH, GA Generic Assay, Brandenburg Technical University Cottbus-Senftenberg, PolyAn GmbH, German Consortium for Translational Cancer Research, Technical University Dresden- Immunology, Institute for Clinical Chemistry and Laboratory Medicine of the University Hospital Carl Gustav Carus in Dresden, Gesellschaft für medizinische und wissenschaftliche genetische Analysen Dresden mbH (Mewigen), Lipotype GmbH, Medipan GmbH, Cybertron GmbH, KDS Radeberger Werkzeugbau GmbH and Resintec GmbH cooperate with each other.

PRAEMED.BIO - Precision medicine through biomarker-based diagnostics

The project is an interdisciplinary cooperation between the companies and research institutes attomol GmbH, GA Generic Assay, Brandenburg Technical University Cottbus-Senftenberg, PolyAn GmbH, German Consortium for Translational Cancer Research, Technical University Dresden - Institute of Immunology, Institute for Clinical Chemistry and Laboratory Medicine of the University Hospital Carl Gustav Carus in Dresden, Gesellschaft für medizinische und wissenschaftliche genetische Analysen Dresden mbH (Mewigen), Lipotype GmbH, Medipan GmbH, Cybertron GmbH, KDS Radeberger Werkzeugbau GmbH and Resintec GmbH.

The Federal Ministry of Education and Research, in cooperation with the Federal Ministry of Health and other partners, has launched the initiative "National Decade against Cancer" for a period of 10 years. Here, national representatives from cancer research, research funding, politics, health care, business and society join forces to combat cancer in a targeted manner (https://www.bmbf.de/de/nationale-dekade-gegen-krebs-7430.html).